Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016', provides an overview of the Sumitomo Dainippon Pharma Co Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Sumitomo Dainippon Pharma Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Sumitomo Dainippon Pharma Co Ltd
- The report provides overview of Sumitomo Dainippon Pharma Co Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Sumitomo Dainippon Pharma Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Sumitomo Dainippon Pharma Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Sumitomo Dainippon Pharma Co Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sumitomo Dainippon Pharma Co Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sumitomo Dainippon Pharma Co Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 7
Sumitomo Dainippon Pharma Co Ltd Snapshot 8
Sumitomo Dainippon Pharma Co Ltd Overview 8
Key Facts 8
Sumitomo Dainippon Pharma Co Ltd - Research and Development Overview 9
Key Therapeutic Areas 9
Sumitomo Dainippon Pharma Co Ltd - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Pipeline Products - Out-Licensed Products 17
Out-Licensed Products/Combination Treatment Modalities 18
Sumitomo Dainippon Pharma Co Ltd - Pipeline Products Glance 19
Sumitomo Dainippon Pharma Co Ltd - Late Stage Pipeline Products 19
Pre-Registration Products/Combination Treatment Modalities 19
Phase III Products/Combination Treatment Modalities 20
Sumitomo Dainippon Pharma Co Ltd - Clinical Stage Pipeline Products 21
Phase II Products/Combination Treatment Modalities 21
Phase I Products/Combination Treatment Modalities 22
Sumitomo Dainippon Pharma Co Ltd - Early Stage Pipeline Products 23
Preclinical Products/Combination Treatment Modalities 23
Discovery Products/Combination Treatment Modalities 25
Sumitomo Dainippon Pharma Co Ltd - Drug Profiles 26
amrubicin hydrochloride - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
blonanserin - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
DSP-0011 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
DSP-1200 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
DSP-6952 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
DSP-7888 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
DSR-17759 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
DSR-6434 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
DSR-71167 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DSR-98776 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
EPI-589 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
HLS-001 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
lurasidone hydrochloride - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
NEP-28 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
obeticholic acid - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
SM-276001 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
SM-295291 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
SM-369926 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecule for Epilepsy - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecule for Pruritus - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecules to Inhibit CaMKII for Undisclosed Indication - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules to Inhibit mPGES-1 for Inflammation - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecules to Target Ras Signaling Pathway for Cancer - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
SMP-304 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
vatiquinone - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
WT-2725 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
WT-4869 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
zonisamide - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Sumitomo Dainippon Pharma Co Ltd - Pipeline Analysis 84
Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Target 84
Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Route of Administration 86
Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Molecule Type 87
Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Mechanism of Action 88
Sumitomo Dainippon Pharma Co Ltd - Dormant Projects 91
Sumitomo Dainippon Pharma Co Ltd - Discontinued Pipeline Products 93
Discontinued Pipeline Product Profiles 94
ceftaroline fosamil 94
DSP-0565 94
DSP-3025 94
DSP-7238 94
DSP-9599 94
emapunil 94
indiplon 95
KGA-3235 95
limaprost 95
rafabegron 95
ranirestat 95
razupenem 95
resequinil 95
rimacalib 95
SEP-225425 95
SEP-226332 96
SEP-227162 96
SEP-227900 96
SMP-028 96
SMP-797 96
Sumitomo Dainippon Pharma Co Ltd - Company Statement 97
Sumitomo Dainippon Pharma Co Ltd - Locations And Subsidiaries 98
Head Office 98
Other Locations & Subsidiaries 98
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 102
Disclaimer 103

List of Tables

Sumitomo Dainippon Pharma Co Ltd, Key Facts 8
Sumitomo Dainippon Pharma Co Ltd - Pipeline by Indication, 2016 10
Sumitomo Dainippon Pharma Co Ltd - Pipeline by Stage of Development, 2016 13
Sumitomo Dainippon Pharma Co Ltd - Monotherapy Products in Pipeline, 2016 14
Sumitomo Dainippon Pharma Co Ltd - Partnered Products in Pipeline, 2016 15
Sumitomo Dainippon Pharma Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 16
Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products in Pipeline, 2016 17
Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 18
Sumitomo Dainippon Pharma Co Ltd - Pre-Registration, 2016 19
Sumitomo Dainippon Pharma Co Ltd - Phase III, 2016 20
Sumitomo Dainippon Pharma Co Ltd - Phase II, 2016 21
Sumitomo Dainippon Pharma Co Ltd - Phase I, 2016 22
Sumitomo Dainippon Pharma Co Ltd - Preclinical, 2016 23
Sumitomo Dainippon Pharma Co Ltd - Discovery, 2016 25
Sumitomo Dainippon Pharma Co Ltd - Pipeline by Target, 2016 84
Sumitomo Dainippon Pharma Co Ltd - Pipeline by Route of Administration, 2016 86
Sumitomo Dainippon Pharma Co Ltd - Pipeline by Molecule Type, 2016 87
Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Mechanism of Action, 2016 89
Sumitomo Dainippon Pharma Co Ltd - Dormant Developmental Projects,2016 91
Sumitomo Dainippon Pharma Co Ltd - Discontinued Pipeline Products, 2016 93
Sumitomo Dainippon Pharma Co Ltd, Other Locations 98
Sumitomo Dainippon Pharma Co Ltd, Subsidiaries 101